Ganaxolone vs Staccato Alprazolam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Ganaxolone
Marketed by Immedica Pharma AB
NCT01963208 · Phase 3 · completed
The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.
Reported efficacy
Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation): Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) (mixed)
Result source: NCT04391569
Staccato Alprazolam
Developed by UCB and partners
NCT03478982 · Phase 2 · completed
The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.
Next expected readout: March 2027 · NCT05077904 (registry estimate)
Reported efficacy
Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)
Result source: NCT03478982
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Ganaxolone | Staccato Alprazolam |
|---|---|---|
| Seizure frequency, % change | -7.5% vs 13.6%−21.1 vs placeboNCT053237344 other results
| —Trial running · NCT05076617 |
| 50% responder rate | 18.8% vs 12.3%+6.5 vs placeboNCT053237343 other results
| —Trial running · NCT05076617 |
| Seizure freedom | 0% vs 2.2%−2.2 vs placeboNCT004655172 other results
| —Trial running · NCT05076617 |
Seizure frequency, % change
- Ganaxolone
- -7.5% vs 13.6%−21.1 vs placeboNCT05323734
4 other results
- -61.5% vs -24.0% NCT03865732
- -17.6% vs 2.0% NCT00465517
- -12.1% vs 4.6% NCT00465517
- -35.9% vs -18.7% NCT03865732
- Staccato Alprazolam
- —Trial running · NCT05076617
50% responder rate
- Ganaxolone
- 18.8% vs 12.3%+6.5 vs placeboNCT05323734
3 other results
- 23.5% vs 14.3% NCT00465517
- 25.5% vs 12.2% NCT00465517
- 50% vs 36.4% NCT03865732
- Staccato Alprazolam
- —Trial running · NCT05076617
Seizure freedom
- Ganaxolone
- 0% vs 2.2%−2.2 vs placeboNCT00465517
2 other results
- 1% vs 0% NCT00465517
- 16.8% vs 8.3% NCT00465517
- Staccato Alprazolam
- —Trial running · NCT05076617
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ganaxolone: 4 of 4 rows · Staccato Alprazolam: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ganaxolone | Staccato Alprazolam |
|---|---|---|
| Dropout rate | 4.2%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results24.6%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 41.2% NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 14.1% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence 12.5%High NCT03350035 · Phase 2 · registry result, not featured evidence 40%Low NCT03350035 · Phase 2 · registry result, not featured evidence 0%Medium NCT03350035 · Phase 2 · registry result, not featured evidence 42.9%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 100%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 50%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 45.5%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 95.1% NCT00512317 · Phase 2 · registry result, not featured evidence 36.4% NCT01002820 · Phase 2 · registry result, not featured evidence 12.2% NCT00465517 · Phase 2 · registry result, not featured evidence | 0%2.0 mgb NCT03478982 · Phase 2 |
| Discontinued due to AEs | 4.2%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results16.8%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 —Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 — NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 7.8% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence —High NCT03350035 · Phase 2 · registry result, not featured evidence —Low NCT03350035 · Phase 2 · registry result, not featured evidence —Medium NCT03350035 · Phase 2 · registry result, not featured evidence 0%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 50%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 10%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 18.2%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 10.6% NCT00512317 · Phase 2 · registry result, not featured evidence 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence 7.1% NCT00465517 · Phase 2 · registry result, not featured evidence | —2.0 mgb NCT03478982 · Phase 2 |
| Serious AEs | 0%Double Blind: Cohort 1 - Ganaxolona NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more results5%Double Blind: Cohort 2 - Ganaxolon NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 7.6%Open Label: Ganaxolone in Double-b NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 6.9%Open Label: Placebo in Double-blin NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 37.3% NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 7.8% NCT05323734 · Phase 3 · registry result, not featured evidence 10% NCT03865732 · Phase 2 · registry result, not featured evidence 25%High NCT03350035 · Phase 2 · registry result, not featured evidence 40%Low NCT03350035 · Phase 2 · registry result, not featured evidence 50%Medium NCT03350035 · Phase 2 · registry result, not featured evidence 14.3%CDKL5 NCT02358538 · Phase 2 · registry result, not featured evidence 50%CSWS NCT02358538 · Phase 2 · registry result, not featured evidence 20%Lennox-Gastaut NCT02358538 · Phase 2 · registry result, not featured evidence 27.3%PCDH19 NCT02358538 · Phase 2 · registry result, not featured evidence 12.2% NCT00512317 · Phase 2 · registry result, not featured evidence 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence 5.1% NCT00465517 · Phase 2 · registry result, not featured evidence | 0%2.0 mgb NCT03478982 · Phase 2 |
| Most frequent reported AEs | a ataxia 12.5% (placebo 0%) sedation 12.5% (placebo 0%) somnolence 12.5% (placebo 9.5%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 show 16 more resultssomnolence 22.3% (placebo 9.5%) dizziness 19% (placebo 0%) fatigue 11.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 somnolence 7.6% (placebo 9.5%) fatigue 5.7% (placebo 0%) headache 5.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 somnolence 16.8% (placebo 9.5%) dizziness 15.6% (placebo 0%) fatigue 8.7% (placebo 0%) NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 hypotension 23.5% (placebo 16.3%) urinary tract infection 19.6% (placebo 8.2%) hypothermia 9.8% (placebo 4.1%) NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3 somnolence 28.1% (placebo 16.9%) pyrexia 15.6% (placebo 16.9%) fatigue 14.1% (placebo 9.2%) NCT05323734 · Phase 3 · registry result, not featured evidence somnolence 40% (placebo 27.3%) aggression 20% (placebo 9.1%) agitation 20% (placebo 0%) NCT03865732 · Phase 2 · registry result, not featured evidence High somnolence 37.5% hypercaprnia 25% hypocalcaemia 25% NCT03350035 · Phase 2 · registry result, not featured evidence Low hypotension 40% haematuria 20% pain 20% NCT03350035 · Phase 2 · registry result, not featured evidence Medium hypokalaemia 25% pain 25% pneumonia 25% NCT03350035 · Phase 2 · registry result, not featured evidence pyrexia 71.4% upper respiratory tract infection 42.9% vomiting 42.9% NCT02358538 · Phase 2 · registry result, not featured evidence dizziness 50% sinusitis 50% somnolence 50% NCT02358538 · Phase 2 · registry result, not featured evidence fungal infection 20% hypersomnia 20% seizure 20% NCT02358538 · Phase 2 · registry result, not featured evidence pyrexia 63.6% somnolence 54.5% fatigue 36.4% NCT02358538 · Phase 2 · registry result, not featured evidence headache 21.1% convulsion 16.3% fatigue 16.3% NCT00512317 · Phase 2 · registry result, not featured evidence headache 18.2% irritability 18.2% aortic aneurysm 9.1% NCT01002820 · Phase 2 · registry result, not featured evidence dizziness 16.3% (placebo 8.2%) fatigue 16.3% (placebo 8.2%) somnolence 13.3% (placebo 2%) NCT00465517 · Phase 2 · registry result, not featured evidence | 2.0 mgb cough 18.4% (placebo 0%) dysgeusia 10.5% (placebo 2.5%) somnolence 10.5% (placebo 2.5%) NCT03478982 · Phase 2 show 2 more results1.0 mg somnolence 18.4% (placebo 2.5%) dysgeusia 15.8% (placebo 2.5%) cough 10.5% (placebo 0%) NCT03478982 · Phase 2 1.0 mg cough 12.5% (placebo 0%) dysmenorrhoea 12.5% (placebo 0%) gastroenteritis viral 12.5% (placebo 0%) NCT03478982 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ganaxolone
show 1 more result
show 1 more result
+ 41 further endpoints in the CSV export.
Staccato Alprazolam
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ganaxolone's landscape · Staccato Alprazolam's landscape